Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange

Conclusion: Ruxolitinib may be life-saving in patients with ABO-incompatible transfusion reaction which follows a severe and catastrophic course.Transfus Med Hemother
Source: Transfusion Medicine and Hemotherapy - Category: Hematology Source Type: research